The University of Chicago Header Logo

Connection

Sandeep Gurbuxani to Male

This is a "connection" page, showing publications Sandeep Gurbuxani has written about Male.
Connection Strength

0.227
  1. Cloaked in a starry sky. Blood. 2014 Apr 10; 123(15):2291.
    View in: PubMed
    Score: 0.024
  2. On a WHIM. Blood. 2013 Feb 07; 121(6):875.
    View in: PubMed
    Score: 0.022
  3. What to do when you suspect gastrointestinal lymphoma: a pathologist's perspective. Clin Gastroenterol Hepatol. 2007 Apr; 5(4):417-21.
    View in: PubMed
    Score: 0.015
  4. Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms. Blood Cancer J. 2024 06 18; 14(1):99.
    View in: PubMed
    Score: 0.012
  5. Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis. Blood Cancer Discov. 2024 May 01; 5(3):164-179.
    View in: PubMed
    Score: 0.012
  6. Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study. JAMA Oncol. 2022 09 01; 8(9):1278-1286.
    View in: PubMed
    Score: 0.011
  7. Comparison of myeloid neoplasms with nonclassic 3q26.2/MECOM versus classic inv(3)/t(3;3) rearrangements reveals diverse clinicopathologic features, genetic profiles, and molecular mechanisms of MECOM activation. Genes Chromosomes Cancer. 2022 02; 61(2):71-80.
    View in: PubMed
    Score: 0.010
  8. Significance of MDR1, MRP1, GSTpi and GSTmu mRNA expression in acute lymphoblastic leukemia in Indian patients. Cancer Lett. 2001 Jun 10; 167(1):73-83.
    View in: PubMed
    Score: 0.010
  9. A series of COVID-19 autopsies with clinical and pathologic comparisons to both seasonal and pandemic influenza. J Pathol Clin Res. 2021 09; 7(5):459-470.
    View in: PubMed
    Score: 0.010
  10. Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. Blood. 2020 11 26; 136(22):2513-2523.
    View in: PubMed
    Score: 0.009
  11. Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib. Br J Haematol. 2020 07; 190(1):e48-e51.
    View in: PubMed
    Score: 0.009
  12. Head and Neck Sinus Histiocytosis with Massive Lymphadenopathy Radiology-Pathology Correlation. Head Neck Pathol. 2019 Dec; 13(4):656-660.
    View in: PubMed
    Score: 0.008
  13. Expression of genes implicated in multidrug resistance in acute lymphoblastic leukemia in India. Ann Hematol. 1998 May; 76(5):195-200.
    View in: PubMed
    Score: 0.008
  14. Immune Reconstitution Following Autologous Stem Cell Transplantation in Patients with High-Risk Neuroblastoma at the Time of Immunotherapy. Biol Blood Marrow Transplant. 2018 03; 24(3):452-459.
    View in: PubMed
    Score: 0.008
  15. Diagnostic evaluation of RNA sequencing for the detection of genetic abnormalities associated with Ph-like acute lymphoblastic leukemia (ALL). Leuk Lymphoma. 2017 04; 58(4):950-958.
    View in: PubMed
    Score: 0.007
  16. Peripheral T-cell lymphomas of follicular helper T-cell type frequently display an aberrant CD3(-/dim)CD4(+) population by flow cytometry: an important clue to the diagnosis of a Hodgkin lymphoma mimic. Mod Pathol. 2016 10; 29(10):1173-82.
    View in: PubMed
    Score: 0.007
  17. Overexpression and knockout of miR-126 both promote leukemogenesis. Blood. 2015 Oct 22; 126(17):2005-15.
    View in: PubMed
    Score: 0.007
  18. RCSD1-ABL2 fusion resulting from a complex chromosomal rearrangement in high-risk B-cell acute lymphoblastic leukemia. Leuk Lymphoma. 2015 Apr; 56(4):1145-7.
    View in: PubMed
    Score: 0.006
  19. A new family with a germline ANKRD26 mutation and predisposition to myeloid malignancies. Leuk Lymphoma. 2014 Dec; 55(12):2945-6.
    View in: PubMed
    Score: 0.006
  20. High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML). Leuk Lymphoma. 2012 Mar; 53(3):445-50.
    View in: PubMed
    Score: 0.005
  21. Extranodal hairy cell leukemia presenting in the lumbar spine. J Neurosurg Spine. 2008 Oct; 9(4):374-6.
    View in: PubMed
    Score: 0.004
  22. Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome. Blood. 2008 Jan 15; 111(2):767-75.
    View in: PubMed
    Score: 0.004
  23. CHOP plus alemtuzumab can induce metabolic response by FDG-PET but has minimal long-term benefits: a case report and literature review. J Gastrointest Cancer. 2007; 38(1):19-23.
    View in: PubMed
    Score: 0.004
  24. CHOP plus alemtuzumab can induce metabolic response by FDG-PET but has minimal long-term benefits: a case report and literature review. J Gastrointest Cancer. 2007; 38(1):59-62.
    View in: PubMed
    Score: 0.004
  25. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood. 2003 Jun 01; 101(11):4298-300.
    View in: PubMed
    Score: 0.003
  26. Incidence, clinical characteristics and early treatment outcome in Indian patients of childhood acute lymphoblastic leukemia with ALL-1 gene rearrangement. Leuk Res. 2001 Aug; 25(8):693-8.
    View in: PubMed
    Score: 0.002
  27. A prospective study on the incidence of hepatitis B & C infections amongst patients with lymphoproliferative disorders. Indian J Med Res. 1998 Feb; 107:78-82.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.